Published in AIDS on January 01, 1997
Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol (2010) 2.20
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol (2004) 2.10
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology (2012) 1.34
Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS One (2013) 1.00
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J Virol (2014) 0.91
A critical question for HIV vaccine development: which antibodies to induce? Science (2014) 0.91
Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One (2010) 0.89
Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV. J Virol (2014) 0.84
Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. J Virol (2016) 0.78
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. J Virol (2016) 0.75
Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. Sci Rep (2017) 0.75
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 5.09
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med (1982) 2.71
Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature (1987) 2.71
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol (2001) 2.50
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
The effectiveness of exercise for the prevention and treatment of antenatal depression: systematic review with meta-analysis. BJOG (2014) 2.45
Effect of a bicultural community health worker on completion of diabetes education in a Hispanic population. Diabetes Care (1997) 2.44
Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol (1999) 2.26
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol (1997) 1.89
Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res (1999) 1.86
Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective. Thorax (2007) 1.86
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS (1989) 1.80
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol (1995) 1.80
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol (2000) 1.76
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med (1997) 1.62
Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology (1993) 1.60
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol (1997) 1.59
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 1.57
A follow-up study of colonic epithelial proliferation as a biomarker ina Native-American family with hereditary nonpolyposis colon cancer. J Natl Cancer Inst (1991) 1.57
Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology (1992) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses (1992) 1.53
Kaposi's sarcoma in homosexual men. A seroepidemiologic case-control study. Ann Intern Med (1984) 1.50
Health-care expenditures for tuberculosis in the United States. Arch Intern Med (1995) 1.48
Stomatal vs. genome size in angiosperms: the somatic tail wagging the genomic dog? Ann Bot (2010) 1.47
Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol (1997) 1.46
Beta 2 microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class I HLA molecules to be used as a virus receptor. J Gen Virol (1987) 1.44
Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens. Clin Diagn Lab Immunol (1997) 1.43
Holoprosencephaly: birth data, benetic and demographic analyses of 30 families. Birth Defects Orig Artic Ser (1975) 1.40
Detection of serum antibody responses in cattle with natural or experimental Neospora infections. J Vet Diagn Invest (1993) 1.39
Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol (1998) 1.39
Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol (2000) 1.39
Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. J Infect Dis (1998) 1.36
Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol (1993) 1.36
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. J Infect Dis (1997) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol (2000) 1.34
Results of a residential indoor PM2.5 sampling program before and after a woodstove changeout. Indoor Air (2008) 1.33
Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome. JAMA (1984) 1.32